

Index

| | Page | | Page |
|--|-------------|---|-------------|
| Accounting policies | 58-61 | Impairment and restructuring costs (note 3) | 64 |
| Acquisitions (notes 39, 42) | 99-100, 101 | Income statement | 54 |
| Associates (note 18) | 83 | Intangible assets (note 16) | 81-82 |
| Audit Committee report | 44 | Interest (notes 6, 7) | 66 |
| Audit fees (note 5) | 65 | Inventories (note 20) | 83 |
| Auditors' report | 53 | Investments in available-for-sale assets (note 19) | 83 |
| Balance sheets | 55 | Key management personnel (note 11) | 68 |
| Board of Directors | 38-39 | Key sources of estimation uncertainty (note 43) | 101 |
| Borrowings (note 24) | 85 | Minority interests (note 33) | 96 |
| Capital expenditure by segment (note 1) | 62-64 | Net debt (note 24) | 85 |
| Capital expenditure to depreciation | 20 | Nomination Committee report | 45 |
| Cash and cash equivalents (note 36) | 98 | Operating and Financial Review | 6-37 |
| Cash flow statements | 56 | Operating leases (notes 4, 38) | 65, 98 |
| Catalysts Division | 8-11 | Operating profit (note 4) | 65 |
| Ceramics Division | 13-15 | Operations | 8-17 |
| Chairman's statement | 2-3 | Outlook | 8 |
| Charitable programmes | 33-34 | Payables (note 23) | 84 |
| Chief Executive's statement | 4-5 | Pensions and other post-employment benefits (note 13) | 23, 71-77 |
| Combined Code Compliance | 41 | Pharmaceutical Materials Division | 13 |
| Commitments (note 38) | 98 | Post balance sheet events (note 42) | 101 |
| Company details | 117 | Precious metal operating leases | 98 |
| Construction contracts (note 21) | 84 | Precious Metal Products Division | 11-13 |
| Contingent liabilities (note 28) | 92 | Process Catalysts and Technologies | 10-11 |
| Corporate Governance | 41-43 | Property, plant and equipment (note 14) | 78-79 |
| Corporate Social Responsibility | 27-37 | Provisions (note 28) | 92 |
| Deferred tax (notes 8, 29) | 66, 93 | Receivables (note 22) | 84 |
| Directors' report | 40 | Recognised income and expense statements | 57 |
| Discontinued operations (note 40) | 101 | Reconciliations from UK GAAP to IFRS (note 44) | 102-108 |
| Dividends (note 9) | 67 | Related parties (note 41) | 101 |
| Earnings per ordinary share (note 10) | 67 | Remuneration report | 46-51 |
| Employee numbers and expense (note 11) | 68 | Research and development (note 4) | 15-17, 65 |
| Employee share ownership trusts (ESOTs) (note 30) | 94 | Reserves (notes 31, 32) | 94-96 |
| Employment policies | 31-32 | Resources | 24-25 |
| Environmental Catalysts and Technologies | 8-10 | Responsibility of directors for accounts | 52 |
| Environment, health and safety | 28-30 | Retained earnings (note 32) | 95-96 |
| Equity (note 32) | 95-96 | Revenue analysis (note 2) | 64 |
| Finance leases (notes 24, 38) | 85, 98 | Review of results | 7-8 |
| Financial assets (note 25) | 86 | Risks and uncertainties | 22-24 |
| Financial highlights | 1 | Segmental information (note 1) | 62-64 |
| Financial liabilities (note 26) | 86 | Senior management | 39 |
| Financial Review | 18-22 | Share capital (note 30) | 94 |
| Financial risk management (note 27) | 21, 86-91 | Share-based payments (note 12) | 69-70 |
| Foreign exchange gains and losses (note 4) | 65 | Shareholder information | 112-113 |
| Fuel Cells | 11 | Social and ethical matters | 33-34 |
| Glossary of terms | 115 | Stakeholder engagement | 27 |
| Goodwill (note 15) | 79-80 | Standards not yet applied | 61 |
| Grants (note 4) | 65 | Strategy and objectives | 7 |
| Guarantees (note 27) | 88 | Subsidiaries (note 17) | 82, 109 |
| History of Johnson Matthey | 114 | Taxation (notes 8, 29) | 66, 93 |
| IFRS transition adjustment for financial instruments (note 34) | 97 | Ten year record | 110-111 |